The Ervebo vaccine, developed by Merck, is a single-dose vaccine. It works by using a modified virus to produce antibodies ...

Merck’s Ebola vaccine offered substantial protection to people vaccinated during the 2018-2020 outbreak in the Democratic Republic of the Congo, with an effectiveness of 84% in those who had ...

Merck makes Ervebo, which is the first Ebola vaccine approved by the U.S. Food and Drug Administration. In 2019, the vaccine was approved in the U.S. for use in people ages 18 and older.

The vaccine rVSVΔG-ZEBOV-GP (Ervebo) not only reduces the risk for Ebola infection but also halves mortality rates. This is the result of a study published in The Lancet Infectious Disease.

The FDA has expanded the approval of Ervebo (Ebola Zaire vaccine, live) to include individuals 12 months of age and older for the prevention of disease caused by Zaire ebolavirus.

The Ebola virus devastated west Africa in 2014, claiming over 11,000 lives in Sierra Leone, Liberia and Guinea.

The Ervebo vaccine, developed by Merck, is a single-dose vaccine. It works by using a modified virus to produce antibodies against Ebola, equipping the immune system to recognise and neutralise ...

The Ervebo vaccine, developed by Merck, is a single-dose vaccine. It works by using a modified virus to produce antibodies against Ebola, equipping the immune system to recognise and neutralise ...